Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Clin Oncol. May 24, 2020; 11(5): 283-293
Published online May 24, 2020. doi: 10.5306/wjco.v11.i5.283
Table 1 Clinical and histopathological characteristics of human epidermal growth factor receptor 2 positive and human epidermal growth factor receptor 2 negative invasive lobular carcinomas patients, n (%)
CharacteristicsHER2+ (n = 87)HER2- (n = 777)Total (n = 864)P value
Age (yr)1.000
≤ 5030 (34.5)272 (35.0)302 (35.0)
> 5057 (65.5)505 (65.0)562 (65.0)
Ethnicity0.594
Chinese68 (78.2)558 (72.1)626 (72.7)
Indian4 (4.6)60 (7.8)64 (7.4)
Malay8 (9.2)68 (8.8)76 (8.8)
Others7 (8.0)88 (11.4)95 (11.0)
ER< 0.001
Negative21 (24.4)46 (5.9)67 (7.8)
Positive65 (75.6)730 (94.1)795 (7.8)
PR0.002
Negative35 (40.2)185 (24.0)220 (25.6)
Positive52 (59.8)587 (76.0)639 (74.4)
Tumour size0.765
0.1-2 cm21 (41.2)230 (38.7)251 (38.9)
> 2 cm30 (58.8)365 (61.3)395 (61.1)
Tumour grade<0.001
Grade 17 (10.1)148 (22.5)155 (21.3)
Grade 242 (60.9)443 (67.3)485 (66.7)
Grade 320 (29.0)67 (10.2)87 (12.0)
Tumour stage0.066
Stage 120 (24.1)216 (30.3)236 (29.7)
Stage 225 (30.1)267 (37.5)292 (36.7)
Stage 327 (32.5)179 (25.1)206 (25.9)
Stage 411 (13.3)50 (7.0)61 (7.7)
Treatment
Chemotherapy150 (66.7)390 (54.2)440 (55.3)0.038
With HER2 therapy47 (54.0)--47 (54.0)
No HER2 therapy12 (13.8)--12 (13.8)
Unknown if any HER2 therapy28 (32.2)--28 (32.2)
Radiotherapy247 (62.7)404 (56.1)451 (56.7)0.276
Surgery373 (92.4)690 (92.1)763 (92.1)0.929
Table 2 Univariate and multivariate Cox proportional hazard regression analysis for overall survival among all 864 invasive lobular carcinomas patients
CharacteristicsUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age (reference: ≤ 50 yr)
> 50 yr2.321.68-3.20< 0.0012.171.37-3.44< 0.001
Ethnicity (reference: Chinese)< 0.00110.0011
Indian2.531.62-3.94< 0.0013.411.78-6.54< 0.001
Malay0.950.50-1.820.8890.980.42-2.290.961
Others0.400.15-1.080.0700.640.19-2.120.462
ER (reference: Negative)
Positive0.740.44-1.240.255
PR (reference: Negative)
Positive0.620.44-0.870.0050.570.35-0.910.018
HER2 (reference: Negative)
Positive1.871.21-2.900.0052.141.16-3.950.016
Tumour size (reference: ≤ 2 cm)
> 2 cm2.431.45-4.06< 0.001
Tumour stage (reference: Stage 1)< 0.0011< 0.0011
Stage 22.331.09-4.990.0301.750.76-4.030.191
Stage 36.983.42-14.25< 0.0014.522.06-9.89< 0.001
Stage 461.8229.73-128.57< 0.00141.7417.95-97.04< 0.001
Tumor grade (reference: Grade 1)< 0.00110.0751
Grade 21.450.83-1.890.1901.050.57-1.930.877
Grade 34.722.55-8.74< 0.0011.890.93-3.840.079
Chemotherapy (reference: No)
Yes0.970.69-1.370.866
Surgery (reference: No)
Yes0.060.04-0.09< 0.001
Radiotherapy (reference: No)
Yes0.890.63-1.270.518
Molecular subtype (reference: Luminal A)0.02510.0021
Basal1.520.79-2.900.2061.130.38-3.290.830
HER2 positive2.080.85-5.100.1084.211.43-12.440.009
Luminal B1.891.16-3.070.0112.521.41-4.490.002
Table 3 Univariate and multivariate Cox proportional hazard regression analysis for breast cancer-specific survival among all 864 invasive lobular carcinomas patients
CharacteristicsUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age (reference: ≤ 50 yr)
> 50 yr2.161.53-3.05< 0.001
Ethnicity (reference: Chinese)< 0.00110.0041
Indian2.601.63-4.14< 0.0012.551.28-5.050.008
Malay0.890.43-1.820.7441.070.43-2.670.885
Others0.320.10-1.020.0540.190.04-0.840.028
ER (reference: Negative)
Positive0.720.42-1.260.255
PR (reference: Negative)
Positive0.610.42-0.880.0080.400.23-0.700.001
HER2 (reference: Negative)
Positive2.081.32-3.260.002
Molecular subtype (reference: Luminal A)0.01110.0041
Basal1.490.72-3.070.2811.160.36-3.770.801
HER2+2.340.95-5.740.0643.741.26-11.090.018
Luminal B2.081.26-3.440.0042.791.44-5.370.002
Tumour size (reference: ≤ 2 cm)
> 2 cm2.761.53-4.97< 0.001
Tumour stage (reference: Stage 1)< 0.0011< 0.001
Stage 23.111.09-8.920.0342.190.74-6.490.159
Stage 313.024.89-34.68< 0.0016.492.35-17.89< 0.001
Stage 4117.7943.5-317.87< 0.00156.2718.44-171.68< 0.001
Tumor grade (reference: Grade 1)< 0.00110.0011
Grade 21.890.96-3.750.0661.630.78-3.440.196
Grade 37.103.44-14.64< 0.0014.161.80-9.620.001
Chemotherapy (reference: No)
Yes1.230.84-1.800.290
Surgery (reference: No)
Yes0.060.04-0.08< 0.0010.230.11-0.51< 0.001
Radiotherapy (reference: No)
Yes0.940.65-1.370.758
Table 4 Univariate and multivariate Cox proportional hazard regression analysis for disease-free survival among all 864 invasive lobular carcinomas patients
CharacteristicsUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Age (reference: ≤ 50 yr)
> 50 yr1.601.11-2.300.0121.631.04-2.550.033
Ethnicity (reference: Chinese)0.001
Indian2.611.52-4.48< 0.001
Malay0.990.48-2.050.984
Others1.991.10-3.580.022
ER (reference: Negative)
Positive1.040.57-1.900.886
PR (reference: Negative)
Positive0.970.65-1.430.876
HER2 (reference: Negative)
Positive1.681.04-2.710.03
Molecular subtype (reference: Luminal A)0.2171
Basal0.980.45-2.120.965
HER2+1.690.62-4.610.304
Luminal B1.670.98-2.830.058
Tumour size (reference: ≤ 2 cm)
> 2 cm2.021.26-3.250.004
Tumour stage (reference: Stage 1)< 0.0011< 0.0011
Stage 21.921.05-3.530.0351.660.83-3.280.149
Stage 35.663.21-9.98< 0.0015.262.76-10.03< 0.001
Stage 40.620.04-10.840.7450.710.04-12.610.813
Tumor grade (reference: Grade 1)< 0.00110.0131
Grade 21.791.02-3.160.0441.320.73-2.400.357
Grade 33.721.89-7.34< 0.0012.691.32-5.500.007
Chemotherapy (reference: No)
Yes1.641.12-2.420.011
Surgery (reference: No)
Yes0.140.08-0.23< 0.001
Radiotherapy (reference: No)
Yes1.571.05-2.340.028